Moreover, according to the ESMO Clinical Practice Guideline for mCRC, right-sided tumors might benefit less in terms of progression-free survival (PFS) and overall survival (OS) from treatment with anti-EGFR mAb compared with left-sided tumors, but anti-EGFR mAb may be effective in terms of tumor shrinkage regardless of tumor sidedness (Cervantes et al. 2023). The gene discussed is EGFR; the disease is neoplasm.